Kornimate/medical-research-clean huggingface dataset:
the effect of pecans on biomarkers of risk for cardiovascular disease and diabetes

Conditions: Cardiovascular Disease Risk; Type 2 Diabetes Risk

Summary: the objective of this randomized, controlled feeding study is to investigate the potential health benefits of a pecan-containing diet. the investigators hypothesize the chronic consumption of pecans will improve an array of biomarkers related to cardiovascular disease and type 2 diabetes risk, including indices of oxidative stress, antioxidant activity, inflammation, endothelial function, and insulin resistance when compared with a control diet that is absent nuts.


Eligibility criteria:
inclusion criteria: * men \& postmenopausal women, age 50 years and over * bmi 25-35 kg/m2 * waist/hip \>0.8 for women and \>0.9 for men * blood pressure between 120/80 and 159/99 exclusion criteria: * cigarette smoking and/or nicotine replacement use * individuals taking estrogen * use of cholesterol-lowering medications * use of blood pressure-lowering medications * regular use of any stomach acid-lowering medications, laxatives (including fiber supplements) or anti-diarrheal medications (prescription or over-the-counter \[otc\]) * cardiovascular (heart) disease * gastrointestinal disease * kidney disease * endocrine disease: including diabetes, unstable thyroid disease * autoimmune disease: including rheumatoid arthritis, gout, lupus, hiv * active treatment for any type of cancer, except basal cell carcinoma, within 1 year prior to study admission * systolic blood pressure \> 159 mmhg and/or diastolic blood pressure \> 99 mmhg * regular use of oral or injectable steroids * gain or loss of \> 10% of body weight within previous 3 months; unwillingness to maintain your weight * regular daily intake of ≥ 2 alcoholic drinks * vegetarians * current allergy to any kind of nut * dietary supplement use, including those containing any vitamins, minerals, herbs, plant concentrates (including garlic, gingko, st. john's wort) homeopathic remedies, probiotics, or fish oil (including cod liver oil), for one month prior to study admission
the impact of pm+for moms intervention on improving mother's mental health in zambia (pm+fm)

Conditions: Depressive Symptoms; Anxiety; Trauma, Psychological

Summary: cmhd are particularly prevalent among women, posing a major threat to their own and their children's wellbeing. despite the high prevalence of cmhd and the existence of effective treatments, interventions supporting women living in low-resourced settings remain limited. this study builds on a parent study (zamcharts nct03991182), which identified a high prevalence of women with anxiety and/or depression. we propose to design, test, and validate a community-based intervention nested within the public primary health system in zambia, to identify and treat women with mild-to-severe cmhds.


Eligibility criteria:
inclusion criteria: * women participating in zamcharts parent study * srq-20 \>7 (clinically significant symptoms of depression or/anxiety), * not planning to move within the next 6 months, * with capacity to consent * not receiving current mental health care. exclusion criteria: * women with active suicidal ideation (determined by paykel=4 or 5), * severe substance use (acok-sud \>4), * mania or psychotic symptoms

Keywords: women low-resourced settings psychosocial intervention
effect of functional endoscopic sinus surgery on eustachian tube function in patients with nasal polypi

Conditions: Functional Endoscopic Sinus Surgery

Summary: this study is conducted to : correlate the incidence of etd with nasal polypi. to evaluate the effects of functional endoscopic sinus surgery on eustachian tube function in patients with nasal polypi

eustachian tube dysfunction (etd) is a frequently applied diagnosis, used when abnormal et function is believed to underlie any of a wide range of symptoms or middle ear (me) abnormalities. two distinct forms of the disorder are recognised, representing different ends of the spectrum of et function: 1)obstructive etd (oetd), in which tubal opening or patency is reduced, and 2) patulous etd (petd), in which the et is too open. it has been suggested that some patients with oetd have either predominantly active dysfunction (failure of muscle-controlled opening), or passive dysfunction (failure of pressure-related opening). there are several explanations to account for the et dysfunction associated with nasal diseases: * mechanical obstruction of et orifice may occur due to nasal mass. * increased secretions from seromucous glands in the pharyngeal portion of et may accumulate and block the tube. * lymphatic stasis due to edema of the submucosa of the tube resulting in compromise of the lumen may produce et dysfunction. * further increase in hydrostatic pressure result in the accumulation of me fluid by transudative process. * tubal dysfunction may be related to deficiency of surfactant that is thought to facilitate tubal opening. it has been postulated that this material is inactivated by inflammation. etd symptoms will decrease post-endoscopic sinus surgery to a level comparable with a non-crs population the use of the etdq-7 has the potential to enhance clinical care by highlighting the impact of etd as well as guiding and evaluating appropriate management. further prospective testing of

Eligibility criteria:
inclusion criteria: * patient who have been diagnosed to have nasal polypi both unilateral and bilateral before doing fess exclusion criteria: * children patient. patients with craniofacial abnormalities or active infection patients with suspected nasal and nasopharyngeal tumour patients with nasal and ear surgery
intelligibility assessment for parkinson's disease

Conditions: Parkinson Disease

Summary: the investigators aim at testing the efficacy of an app to measure sentence intelligibility in noise in speakers with parkinson's disease and in healthy controls.

close to 90% of people with parkinson's disease develop voice problems during the course of the disease. these problems lead to reduced intelligibility, which entails a subsequent reduction in social participation and overall quality of life. the current study will focus on developing and pilot-testing an app to measure the intelligibility of people with pd and of healthy controls. in order to test the app's efficacy, speakers will read a set of 50 sentences that will be embedded in noise for measurement purposes. a group of listeners will also transcribe the spoken sentences to correlate their performance to that of the app. the ultimate purpose of this investigation is to improve self-monitoring and self-sufficiency in people with pd. the study is expected to last 12 months.

Eligibility criteria:
speakers with pd: inclusion criteria: * have a medical diagnosis of parkinson's disease * have experienced changes in your voice (e.g., your voice has "lost its strength") and your voice is a current concern * have not received individual speech therapy for the past 2 years (group therapy is ok) * have a stable medication schedule * have not received dbs (deep brain stimulation) * are a native speaker of american english exclusion criteria: * if criteria above are not met healthy controls: inclusion criteria: * be a native speaker of american english * have no history of neurological impairment * have no history of speech or language problems exclusion criteria: * if criteria above are not met listeners: inclusion criteria: * be a native speaker of american english * be between 18-55 years old * have no history of speech-language-hearing problems * pass a free hearing screening * have received the covid19 vaccine exclusion criteria: * if criteria above are not met

Keywords: intelligibility voice disorders dysarthria
empagliflozin-based quadruple therapy vs basal insulin-based therapy

Conditions: Diabetes Mellitus, Type 2

Summary: this study aimed to evaluate the long-term effectiveness and safety of the empagliflozin as add-on thearpy compared to basal insulin-based antidiabetic agents (oads) combination therapy in patients with type 2 diabetes inadequately controlled on triple oads in a real clinical practice.

this study aimed to evaluate the long-term effectiveness and safety of the empagliflozin as add-on thearpy compared to basal insulin-based antidiabetic agents (oads) combination therapy in patients with type 2 diabetes inadequately controlled on triple oads in a real clinical practice.

Eligibility criteria:
inclusion criteria: * inadequately controlled with triple oads (metformin, glimepiride, dipeptidyl peptidase-4 inhibitor) showing hba1c 7.5-12.0% exclusion criteria: * type 1 diabetes * gestional diabetes * diabetes due to secondary causes * receiving anticancer treatment * receiving glucocorticoids or immune-suppressants * have been treated with sodium glucose co-transporter 2 inhibitors for more than 7 consecutive days within 3 months before entering the study * have been treated with any type of insulin for more than 7 consecutive days within 3 months before entering the study

Keywords: type 2 diabetes mellitus sodium-glucose co-transporter 2 inhibitor empagliflozin insulin glargine insulin degludec
microbubble-enhanced clotbust treatment of acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the study is designed to examine the safety, tolerability, and activity of a combination of microbubbles (perflutren lipid microsphere \[definity®\]) and continuous monitoring with 2 mhz transcranial doppler ultrasound (tcd) as an adjunctive therapy to tissue plasminogen activator (tpa) treatment in subjects with acute ischemic stroke.


Eligibility criteria:
inclusion criteria: * measurable focal neurological deficit (national institutes of health stroke scale \[nihss\] score \> 4 points) * tpa eligible * occlusion of the middle cerebral artery exclusion criteria: * right to left cardiac shunt * uncontrolled hypertension * absent temporal windows

Keywords: acute ischemic stroke microbubbles transcranial doppler ultrasound tibi symptomatic intracranial hemorrhage modified rankin scale recanalization perflutren
sglt2 inhibitors, ketones, and cardiovascular benefit research plan

Conditions: Type2 Diabetes; Heart Failure With Preserved Ejection Fraction

Summary: the study team will examine the effects of sglt2i (and sglt2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.

the study team will examine effects of elevated plasma ketones caused by 12-week treatment with an sglt2i (empagliflozin) treatment in participants with t2dm and hf. the study team will focus on three possible mechanisms of action for these effects and test the following: (i) skeletal muscle bioenergetics. using 31p-mrs, the team will quantitate phosphocreatine \[pcr\], atp, inorganic phosphate, phosphodiester, and intracellular ph. with 1h-mrs, and will measure intramyocellular lipid content at rest and atpmax production after exercise. the team will examine the relationships between phosphorous metabolite concentrations, intramyocellular lipid content, and atp generation before and after 12 weeks of sglt2 inhibition. (ii) cardiopulmonary functional capacity. (iii) improvements in patient-reported outcomes (pro). the patient-reported outcomes measure information system (promis) item bank v2.0 - physical function - short form 20a will be used to evaluate self-reported physical function and well-being. this tool is a well-developed and validated method to obtain patient self-reported parameters of health in adults.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * class ii-iii new york heart association (nyha) heart failure and reduced ejection fraction (ef) \<50% * age 18-80 years * bmi 23-38 kg/m2 * glycated hemoglobin (hba1c) 5.5-10% * blood pressure (bp) ≤ 145/85 mmhg * estimated glomerular filtration rate (egfr) ≥30 ml/min•1.73 m2 * stable dose of guideline-directed medications for heart failure and diabetes * stable body weight (±4 pounds) over the last 3 months * does not suffer from severe claustrophobia * no contraindication for mri (metal plates, screws, shrapnel, pins, or cardiac pacemaker) exclusion criteria: * subjects treated with an sglt2 inhibitor, a glucagon-like peptide-1 receptor agonist (glp-1 ra) or pioglitazone * pregnancy, lactation or plans to become pregnant * allergy/sensitivity to study drugs or their ingredients * cancer * current drug or alcohol use or dependence * inability or unwillingness of individual or legal guardian/representative to give written informed consent

Keywords: ketones cardiovascular benefit
pectoral nerve block versus paravertebral block in the incidence of chronic pain after mastectomy:

Conditions: Paravertebral Block; Pectoral Nerve Block; Chronic Pain; Mastectomy; Lymphedema

Summary: chronic pain after mastectomy is frequent and an important healthcare priority because of its effect on quality of life. although the association between the severity of acute pain after surgery and the likelihood of chronic pain is known, their causal relationship has not been clarified. mastectomy, frequently done for the management of breast cancer, is associated with significant acute postoperative pain and limited shoulder movement.

general anesthesia with postoperative nsai d and opioids is a commonly used technique for postoperative analgesia after breast surgeries. patients with mastectomy under general anesthesia commonly have pain in the axilla and upper limb that increases hospital stay, costs, and postoperative complications .thoracic paravertebral block can be performed for analgesia after breast surgery. ultrasound usage gave an accurate reading of the depth to the paravertebral space and can be used during the whole technique. breast surgery is usually done with axillary dissection and can be done at single or multiple levels of thoracic paravertebral blocks .thoracic paravertebral block is associated with multiple complications such as hypotension, pneumothorax, sympathetic block, central spread of local anesthesia or failed block which may cause limitations in the technique. the use of ultrasound in anesthesia increases the success rate of the block and decreases the incidence of variable complications .on the other hand, many interfascial plane blocks have been described. pectoral nerve block (pecs) has been described as interfascial plane blocks and provide analgesic adjuvants for breast surgery with or without axillary dissection. the block was described as an injection of local anesthetic between the pectoralis major and minor muscles (pec i) and between pectoralis minor and serratus anterior muscle (pec 2) .

Eligibility criteria:
inclusion criteria: * asa grade i, ii, or iii female patients in the age group of 20-65 years * with body mass index (bmi) of 25-35 who were undergoing mastectomy with or without axillary lymph node or sentinel lymph node dissection or partial mastectomy (sparing the skin, areola, and nipple) with axillary lymph node dissection exclusion criteria: * male sex; patient refusal, * a life expectancy less than 2 yr; * active malignant disease; pregnant or breastfeeding women; * bilateral surgery; ipsilateral breast surgery in the past 3 yr;
dyg versus cetrorelix in oocyte donation

Conditions: Infertility, Female; Fertility Disorders

Summary: prospective controlled study to assess the reproductive outcomes of od recipients in which the donors were subjected to the dyg protocol (20mg/day) compared with those subjected to the short protocol with cetrorelix (0.25 mg/day) from day 7 or since a leading follicle reached 14 mm. the od cycles were triggered with triptoreline acetate and the trigger criterion was ≥3 follicles of diameter \>18mm.


Eligibility criteria:
inclusion criteria: * oocyte donors between 21 and 30 years old, with regular menstrual cycles (24-35 d) and a body mass index (bmi) between 18 and 28 kg/m2 without any relevant personal or family history exclusion criteria: * amh less than 3 ng/dl * a positive screening for sexually transmitted diseases

Keywords: gonadotrophin-releasing hormone (gnrh) analogues ovarian stimulation oocyte donation progestin-primed ovarian stimulation dydrogesterone
periodic limb movement and genetic generalized epilepsy

Conditions: Epilepsy Generalized Idiopathic Not Intractable

Summary: the study aimed to study the correlation between periodic limb movement occurring during sleep and the different parameters of genetic generalized epilepsy

although periodic limb movements are prevalent among patients with epilepsy, the exact relationship between these movements and epilepsy remains elusive. objective: the aim of this work was to study the periodic limb movements among patients with genetic generalized epilepsy in relation to different clinical characteristics and seizure recurrence. methods: sixty individuals participated in this study: thirty of them were newly diagnosed with genetic generalized epilepsy and thirty were healthy individuals. sleep quality was assessed using the pittsburgh sleep quality index questionnaire, and a standard polysomnographic study was conducted to all subjects. all patients then received sodium valproate in therapeutic doses and were followed up for six months. electroencephalogram (eeg) was done after the follow-up period and seizure recurrence was assessed. accordingly, patients were classified into three groups according to clinical seizure recurrence and follow-up eeg findings. periodic limb movement index and frequency were compared among the patients' groups and were correlated with different clinical characteristics.

Eligibility criteria:
inclusion criteria: * newly diagnosed with genetic generalized epilepsy according to the ilae 2010 criteria * did not previously receive aeds. * the clinical seizures were either eyewitnessed by physicians or video-recorded to ensure they were true epileptic seizures. * at least two unprovoked seizures occurring \>24 hours apart exclusion criteria: * patients with pre-existing psychiatric illnesses * patients with seizures due to toxic or metabolic causes (including glucose disturbance, uremia, and electrolytes disturbance), infections, or structural causes (such as neoplasms) * patients using hypnotic drugs

Keywords: generalized epilepsy, idiopathic, periodic limb movement
childhood asthma mentoring program for parents

Conditions: Asthma

Summary: there are 7.1 million children with asthma. asthma is the cause of 10.5 million missed days of school, 7.5 million outpatient visits, 640,000 ed visits, and 157,000 hospitalization visits in 2008. recent work has demonstrated that trained peer mentors (individuals from the community) can be effective in reducing hospitalizations for asthmatic children. this study will evaluate the efficacy of technology-driven parent-to-parent mentoring to reduce asthma-related pediatric hospitalizations and emergency department visits.


Eligibility criteria:
inclusion criteria: * parent of child with persistent asthma, prescription of controller medications, and at least one asthma exacerbation in the past year exclusion criteria: * parent has no access to smartphone

Keywords: peer mentor health coach parent support parent mentor
training in goal-directed attention regulation for individuals with brain injury

Conditions: Brain Injury

Summary: brain injuries affect the lives of numerous veterans. this study examines how the brain is affected by injury and how rehabilitation training for attention dysfunction may change brain functioning.

traumatic brain injuries (tbi) are a leading cause of long-term disability among combat veterans. the most common and persistent sequelae after tbi are cognitive-behavioral deficits in 'executive control' and 'attention' functions. such abnormalities may directly contribute to poor long-term outcomes as well as impede rehabilitation of dysfunction in other cognitive and motor domains. effective treatments would potentially make a major impact in improving functional outcomes, but consistently effective treatments are not available. the overall goal of this research is to improve the investigators' understanding of plasticity in brain function after tbi and to develop improved cognitive neurorehabilitation treatments. the intervention involves individual and group-based training in cognitive skills.

Eligibility criteria:
inclusion criteria: * history of traumatic brain injury * greater than 1 week from injury * residual dysfunction related to attention and executive control exclusion criteria: * aphasia * active illicit drug use * severe depression * contraindications to mri scanning

Keywords: attention rehabilitation training functional mri executive function brain injury
fluocinolone acetonide in diabetic macular edema (fame) extension study

Conditions: Diabetic Macular Edema

Summary: this study will assess the safety and utility of the new inserter for the administration of iluvien in subjects with diabetic macular edema.


Eligibility criteria:
inclusion criteria: 1. subjects who previously participated in the fame studies and subjects with chronic dme considered insufficiently responsive to available therapies. 2. in the judgment of the investigator, the subject will benefit from treatment with iluvien. 3. ability and willingness to comply with the treatment and follow up procedures. 4. ability to understand and sign the informed consent form. no expectation that subject will be moving out of the area of the clinical center to an area not covered by another clinical center during the next 12 months. exclusion criteria: 1. pregnant, lactating females or females of childbearing potential (unless using reliable contraception, i.e. double barrier, surgical sterilization, oral contraceptives, norplant, intrauterine device (iud) 2. glaucoma, defined as glaucomatous anatomical changes of the optic disc and/or visual field changes at screening in the study eye 3. retinal or choroidal neovascularization due to ocular conditions other than diabetic retinopathy (e.g., presumed ocular histoplasmosis, high myopia (spherical equivalent \> 8 diopters), macular degeneration) 4. any active viral, fungal or bacterial disease of the cornea or conjunctiva or any history of a potentially recurrent infection which could be activated by treatment with a steroid, (e.g., ocular herpes simplex virus) 5. known or suspected hypersensitivity to any of the ingredients of the investigational product or to other corticosteroids 6. history of uncontrolled iop elevation with steroid use that did not respond to topical therapy or iop-lowering procedure 7. history or presence of any disease or condition (malignancy) that in the investigator's opinion would preclude study treatment or follow-up 8. any lens opacity which significantly impairs vision, in the opinion of the investigator. 9. peripheral retinal detachment in prospective area of insertion 10. participation in another clinical trial within 12 weeks before the screening visit or during the study